Citadel Advisors’s BeOne Medicines Ltd ONC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $307M | Buy |
1,032,298
+498,781
| +93% | +$161M | 0.05% | 305 |
|
|
2025
Q4 | $162M | Buy |
533,517
+497,312
| +1,374% | +$163M | 0.02% | 586 |
|
|
2025
Q3 | $12.3M | Sell |
36,205
-500,951
| -93% | -$152M | ﹤0.01% | 2953 |
|
|
2025
Q2 | $130M | Sell |
537,156
-445,005
| -45% | -$109M | 0.02% | 598 |
|
|
2025
Q1 | $267M | Buy |
982,161
+665,048
| +210% | +$155M | 0.05% | 276 |
|
|
2024
Q4 | $58.6M | Buy |
317,113
+270,079
| +574% | +$55.2M | 0.01% | 1143 |
|
|
2024
Q3 | $10.6M | Buy |
47,034
+41,254
| +714% | +$7.42M | ﹤0.01% | 2816 |
|
|
2024
Q2 | $825K | Buy |
5,780
+5,681
| +5,738% | +$876K | ﹤0.01% | 6993 |
|
|
2024
Q1 | $15.5K | Sell |
99
-11,722
| -99% | -$1.89M | ﹤0.01% | 13185 |
|
|
2023
Q4 | $2.13M | Buy |
11,821
+7,284
| +161% | +$1.32M | ﹤0.01% | 5244 |
|
|
2023
Q3 | $816K | Sell |
4,537
-31,854
| -88% | -$6.3M | ﹤0.01% | 6999 |
|
|
2023
Q2 | $6.49M | Buy |
36,391
+22,207
| +157% | +$5.11M | ﹤0.01% | 3264 |
|
|
2023
Q1 | $3.06M | Sell |
14,184
-26,910
| -65% | -$6.45M | ﹤0.01% | 4603 |
|
|
2022
Q4 | $9.04M | Buy |
41,094
+14,263
| +53% | +$2.62M | ﹤0.01% | 2970 |
|
|
2022
Q3 | $3.62M | Sell |
26,831
-15,044
| -36% | -$2.58M | ﹤0.01% | 4438 |
|
|
2022
Q2 | $6.78M | Buy |
41,875
+38,567
| +1,166% | +$6.02M | ﹤0.01% | 3252 |
|
|
2022
Q1 | $624K | Buy |
3,308
+1,370
| +71% | +$291K | ﹤0.01% | 8854 |
|
|
2021
Q4 | $525K | Sell |
1,938
-30,439
| -94% | -$10.3M | ﹤0.01% | 9584 |
|
|
2021
Q3 | $11.8M | Buy |
32,377
+25,332
| +360% | +$8.28M | ﹤0.01% | 2789 |
|
|
2021
Q2 | $2.42M | Buy |
7,045
+2,260
| +47% | +$749K | ﹤0.01% | 6130 |
|
|
2021
Q1 | $1.67M | Sell |
4,785
-9,103
| -66% | -$3.01M | ﹤0.01% | 6846 |
|
|
2020
Q4 | $3.59M | Sell |
13,888
-797
| -5% | -$219K | ﹤0.01% | 4272 |
|
|
2020
Q3 | $4.21M | Buy |
14,685
+12,888
| +717% | +$3.03M | ﹤0.01% | 3409 |
|
|
2020
Q2 | $339K | Sell |
1,797
-9,398
| -84% | -$1.53M | ﹤0.01% | 7716 |
|
|
2020
Q1 | $1.38M | Sell |
11,195
-10,180
| -48% | -$1.59M | ﹤0.01% | 4770 |
|
|
2019
Q4 | $3.54M | Buy |
+21,375
| New | +$3.55M | ﹤0.01% | 3557 |
|
|
2019
Q3 | – | Sell |
-21,662
| Closed | -$2.88M | – | 9857 |
|
|
2019
Q2 | $2.69M | Buy |
21,662
+8,054
| +59% | +$1.02M | ﹤0.01% | 4041 |
|
|
2019
Q1 | $1.8M | Sell |
13,608
-3,373
| -20% | -$455K | ﹤0.01% | 4641 |
|
|
2018
Q4 | $2.38M | Buy |
16,981
+11,168
| +192% | +$1.48M | ﹤0.01% | 3875 |
|
|
2018
Q3 | $1M | Sell |
5,813
-14,765
| -72% | -$2.48M | ﹤0.01% | 5546 |
|
|
2018
Q2 | $3.16M | Buy |
+20,578
| New | +$3.67M | ﹤0.01% | 3404 |
|
Other funds holding ONC
BBA
HA
SL
Citadel Advisors's ONC Position: Q1 2026 in Review
Citadel Advisors increased its BeOne Medicines Ltd (ONC) stake by 93% in Q1 2026, buying an estimated $161M and bringing the position to 1,032,298 shares worth $307M. The position accounts for 0.05% of the portfolio, ranked #305.
Citadel Advisors first reported a position in ONC in Q2 2018 and has held it in 31 quarters since. 282 funds tracked by Wall St. Rank hold ONC as of Q1 2026.
- Citadel Advisors held 1,032,298 shares of BeOne Medicines Ltd worth $307M as of Q1 2026.
- Citadel Advisors bought 498,781 BeOne Medicines Ltd shares in Q1 2026, an estimated $161M.
- BeOne Medicines Ltd made up 0.05% of Citadel Advisors's portfolio in Q1 2026, its #305 holding.
- Citadel Advisors first reported a position in BeOne Medicines Ltd in Q2 2018 and has held it in 31 quarters since.
- 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.